Organisation paid for research Program year 2024 Source: CMS Open Payments

USF Physicians Group

Neither a doctor nor a teaching hospital

Research payments

$10,241

9 payments

Through program year 2024, USF Physicians Group is reported as receiving $10,241 in research payments, across 9 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$357	1
2021	Research	$1,936	1
2020	Research	$3,346	2
2019	Research	$4,602	5

Breakdown

Who paid Research payments · program years 2019–2024

Merck Sharp & Dohme Corporation $9,884 8 payments
Pfizer Inc. $357 1 payment

Studies the money was for Research payments · program years 2019–2024

A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled ClinicalTrial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once DailyVersus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each inCombination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na ve HIV-1Infected Subjects $4,476 2 payments
A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na ve HIV-1 Infected Subjects $3,346 2 payments
A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na HIV-1 Infected Subjects $1,936 1 payment
An Openlabel Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis $357 1 payment
A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled ClinicalTrial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once DailyVersus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each inCombination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na ve HIV-1Infected Subjects $74 1 payment
A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled ClinicalTrial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once DailyVersus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each inCombination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na ve HIV-1Infected Subjects $52 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.